

NHS Grampian Formulary Group Decisions for SMC advice published April 2024



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2024.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

April 2024

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Bevespi Aerosphere® 7.2micrograms/5micrograms pressurised inhalation, suspension (glycopyrronium/formoterol fumarate)	2652	As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Not routinely available as there is a local preference for alternative medicines	16/04/2024
daridorexant 25mg, 50mg film-coated tablets (Quviviq®)	2611	Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. SMC restriction: in patients who have failed cognitive behavioural therapy for insomnia (CBT-I) or for whom CBT-I is unsuitable or unavailable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	2635	In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)	2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
mirikizumab 100mg solution for injection in pre-filled pen, 300mg concentrate for solution for infusion (Omvo®)	2650	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
ritlecitinib tosylate 50mg hard capsules (Litfulo®)	2610	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12,5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)	2633	<p>For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:</p> <ul style="list-style-type: none">- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. <p>SMC restriction: in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024